Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is expected to be posting its resultson Monday, August 17th. Analysts expect the company to post earnings of ($0.1139) per share and revenue of $4.2290 million for the quarter.
Carisma Therapeutics Trading Down 12.0%
Shares of NASDAQ CARM opened at $0.00 on Friday. The company has a market capitalization of $92,059.00, a P/E ratio of 0.00 and a beta of -9.09. Carisma Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.56. The stock has a 50 day moving average of $0.01 and a 200-day moving average of $0.02.
Institutional Trading of Carisma Therapeutics
An institutional investor recently bought a new stake in Carisma Therapeutics stock. Jane Street Group LLC purchased a new stake in Carisma Therapeutics Inc. (NASDAQ:CARM – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 44.27% of the company’s stock.
About Carisma Therapeutics
Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.
The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.
Read More
- Five stocks we like better than Carisma Therapeutics
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
